Cencora Stock

$292.87

0.51% day before yesterday

NYSE, Jul 18, 10:00 pm CET

ISIN

US03073E1055

Symbol

COR

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Health

Industry

Specialist medical trade

Overview Dividends Analysts Charts News Strategies

Cencora Stock price

$292.87

+190.68 186.59% 5Y

NYSE, Closing price Fri, Jul 18 2025

-1.51 0.51%

ISIN

US03073E1055

Symbol

COR

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Health

Industry

Specialist medical trade

Key metrics

Basic

Market capitalization

$56.8b

Enterprise Value

$62.6b

Net debt

$5.9b

Cash

$2.0b

Shares outstanding

193.8m

Valuation (TTM | estimate)

P/E

33.8 | 18.3

P/S

0.2 | 0.2

EV/Sales

0.2 | 0.2

EV/FCF

17.5

P/B

56.1

Dividends

DPS

$2.04

Yield 1Y | 5Y

0.7% | 1.3%

Growth 1Y | 5Y

5.2% | 5.0%

Payout 1Y | 3Y

27.1% | 24.2%

Increased

19 Years

Financials (TTM | estimate)

Revenue

$310.2b | $324.9b

EBITDA

$4.3b | $4.7b

EBIT

$3.2b | $4.2b

Net Income

$1.7b | $3.1b

Free Cash Flow

$3.6b

Growth (TTM | estimate)

Revenue

12.2% | 10.5%

EBITDA

9.3% | 14.2%

EBIT

13.1% | 39.1%

Net Income

-8.6% | 105.1%

Free Cash Flow

69.3%

Financial Health

Equity Ratio

1.0%

Return on Equity

233.6%

ROCE

17.8%

ROIC

Debt/Equity

7.8

EPS

$8.7

FCF per Share

$18.5

Short interest

5.9%

Employees

44k

Rev per Employee

$6.7m

As a Free StocksGuide user, you can view scores for all 7,009 stocks worldwide.

Get Started for Free Today

Cencora Stock Analysis

Unlock Scores for Free

??

22 Analysts have issued a Cencora forecast:

15x Buy

68%

7x Hold

32%

More details on Analyst Estimates Including Price Targets

22 Analysts have issued a Cencora forecast:

Buy

68%

Hold

32%

Analyst Estimates with Stock Price Targets

Financial data from Cencora

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	310,232 310,232	12% 12% 100%
- Direct Costs	300,011 300,011	12% 12% 97%
Gross Profit	10,221 10,221	9% 9% 3%
- Selling and Administrative Expenses	5,946 5,946	8% 8% 2%
- Research and Development Expense	- -	- -
EBITDA	4,275 4,275	9% 9% 1%
- Depreciation and Amortization	1,088 1,088	0% 0% 0%
EBIT (Operating Income) EBIT	3,187 3,187	13% 13% 1%
Net Profit	1,693 1,693	9% 9% 1%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Cencora Stock News

Neutral

Business Wire

●

17 days ago

Cencora Announces Date and Time for Third Quarter Fiscal 2025 Earnings Release

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2025 on Wednesday, August 6, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on August 6, 2025. Participating in the conference call will be: Robert ...

Neutral

Business Wire

●

about 2 months ago

Cencora Elects Lori J. Ryerkerk to Its Board of Directors

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Lori J. Ryerkerk as a new independent director, effective June 1, 2025. “Ms. Ryerkerk's experience in complex, global supply chains will further strengthen the Board's expertise as we continue supporting the company's long-term growth. Her appointment reflects the Cencora Board'...

Positive

Seeking Alpha

●

2 months ago

Cencora Continues To Deliver As A Healthcare Distributor With Further Growth Signs

Cencora gets a buy rating, agreeing with today's consensus from Wall St. The sector and macro environment points to continued demand for the healthcare supplies and niche specialty drugs Cencora can distribute. Future share price targets point to significant potential upside over 3 years, justifying a buy despite the stock trading above average now.

More Cencora News

Company Profile

AmerisourceBergen Corp. engages provision of pharmaceutical products and business solutions that improve access to care. It operates through the Pharmaceutical Distribution Services and Other segments. The Pharmaceutical Distribution Services segment distributes a comprehensive offering of brand-name, specialty brand-name & generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies & equipment, outsourced compounded sterile preparations, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent & chain retail pharmacies, mail order pharmacies, medical clinics, long-term care & alternate site pharmacies, and other customers. The Other segment focuses on global commercialization services and animal health and includes ABCS, World Courier, and MWI. The company was founded in 1947 and is headquartered in Chesterbrook, PA.

Head office	United States
CEO	Robert Mauch
Employees	44,000
Founded	1947
Website	www.cencora.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now